The invention pertains to a functionalizable and enzyme-activatable fluorescent probe and methods for monitoring the activity of amine oxidases. Amine oxidases catalyze the oxidative deamination, e.g. of the ε-amine of a lysine to an aldehyde which in turn can form covalent bonds with neighboring side chains, e.g. in the context of collagen cross-linking. Amine oxidase activity can be correlated with collagen-associated diseases including pulmonary and hepatic fibrosis, cardiomyopathy and tumor metastasis.

The present invention relates to inhibitors of VAP-1 and their use as medicaments in treating fibrotic conditions. Furthermore, the present invention relates to a method of diagnosing a fibrotic condition on the basis of elevated level of soluble VAP-1 or SSAO activity in a bodily fluid, and to a kit for use in said diagnostic method.

Provided are therapeutic, diagnostic, and prognostic methods for disease, including diseases associated with fibrosis and cancer using agents that bind to, inhibit, and/or detect lysyl oxidase-like 2 (LOXL2), and agents, compositions, kits, assay systems, and devices for use with such methods.

Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.

Disclosed is a method for diagnosing a mood disorder or susceptibility to a mood disorder, including depressive disorders and bipolar disorder, from a biological sample taken from a subject. The method includes detecting markers of monoamine oxidase-A (MAO-A) in the biological sample; determining MAO-A concentration from the markers; and correlating the MAO-A concentration in the biological sample to a control group which does not have a mood disorder in order to diagnose or determine susceptibility to the mood disorder in the subject. Also disclosed is a method of detecting peripheral markers of MAO-A for the diagnosis of a mood disorder or susceptibility to a mood disorder. Also provided are polypeptide markers.

Compositions containing monoamine oxidase inhibitors prepared by removal of alcohol from agave-derived beverages are disclosed.

The present invention relates to novel bioprobes which are capable of binding to certain amine oxidase enzymes. These bioprobes are useful in methods of detecting and determining the concentration of certain amine oxidase enzymes in a sample as well as in methods for the quantitative assessment of inhibition of certain amine oxidases.

Particles of a sustained-release gel which is converted into a sol by reacting with a product produced by a reaction of biomolecules with an enzyme, are disposed on a measurement unit, and a measurement target biomolecule is brought into contact with the particles. Due to this contact, a product is produced according to a reaction of the biomolecule with the enzyme contained in the particles. According to the reaction with the produced product, the sustained-release is converted into a sol, and a plurality of contained detection molecules are released to the outside of the particles.

An object of the present invention is to provide a convenient sampling method and kit for histamine measurement. The present invention provides a method and a kit which involve non-invasively sampling a specimen, and detecting histamine from the obtained sample.

There is provided a novel quantification method for quantifying a concentration of EAP, which is a biomarker of depression, an enzyme for quantitation, a composition for quantitation, a kit for quantitation or a sensor for quantitation. There is provided a quantification method of ethanolamine phosphate by adding oxidoreductase to a sample containing ethanolamine phosphate. A mediator may be reduced by adding the oxidoreductase, and the reduced mediator may be reacted with a reagent to determine a concentration of ethanolamine phosphate. In addition, hydrogen peroxide produced by adding the oxidase as the oxidoreductase may be reacted with a reagent to determine a concentration of the ethanolamine phosphate.